Untold story of human cervical cancers: HPV-negative cervical cancer

키워드

참고문헌 (71)

1. Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Durst M, "A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions", Proc Natl Acad Sci U S A, 80, pp.3812~3815 (1983)
3. Li N, "Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide : variation by geographical region, histological type and year of publication", Int J Cancer, 128, pp.927~935 (2011)
4. Xing B, "Human papillomavirus-negative cervical cancer : a comprehensive review", Front Oncol, 10, pp.606335~ (2020)
5. Petry KU, "Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers", Papillomavirus Res, 4, pp.85~89 (2017)
6. Castle PE, "Comparison of cervical cancer screening results among 256, 648 women in multiple clinical practices", Cancer Cytopathol, 123, pp.566~ (2015)
7. Cancer Genome Atlas Research N, "Integrated genomic and molecular characterization of cervical cancer", Nature, 543, pp.378~384 (2017)
8. Baay MF, "Prevalence of human papillomavirus in elderly women with cervical cancer", Gynecol Obstet Invest, 52, pp.248~251 (2001)
9. Nicolas I, "HPV-negative tumors of the uterine cervix", Mod Pathol, 32, pp.1189~1196 (2019)
10. Li P, "Prognostic value of HPV DNA status in cervical cancer before treatment : a systematic review and meta-analysis", Oncotarget, 8, pp.66352~66359 (2017)
11. Zampronha Rde A, "Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer", Clinics(Sao Paulo), 68, pp.809~814 (2013)
12. Tommasino M, "The role of TP53 in cervical carcinogenesis", Hum Mutat, 21, pp.307~312 (2003)
13. Tjalma WA, "A crosssectional, multicentre, epidemiological study on human papillomavirus(HPV)type distribution in adult women diagnosed with invasive cervical cancer in Belgium", Facts Views Vis Obgyn, 7, pp.101~108 (2015)
14. Romero-Pastrana F, "Detection and typing of human papilloma virus by multiplex PCR with type-specific primers", ISRN Microbiol, 2012, pp.186915~ (2012)
15. Rodriguez-Carunchio L, "HPV-negative carcinoma of the uterine cervix : a distinct type of cervical cancer with poor prognosis", BJOG, 122, pp.119~127 (2015)
16. Iftner T, "Study comparing human papillomavirus(HPV)real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays", J Clin Microbiol, 47, pp.2106~2113 (2009)
17. Jarrom D, "Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis : a rapid systematic review", BMJ Evid Based Med, 27, pp.33~45 (2022)
18. Syrjanen K, "Human papillomavirus(HPV)infections involved in the neoplastic process of the uterine cervix as established by prospective follow-up of 513 women for two years", Eur J Gynaecol Oncol, 8, pp.5~16 (1987)
19. Pratili MA, "Human papillomaviruses in the epithelial cells of the cervix uteri:frequency of types 16 and 18. Preliminary results of a clinical, cytologic and viral study", J Gynecol Obstet Biol Reprod (Paris), 15, pp.45~50 (1986)
20. Weisbrod CR, "In vivo protein interaction network identified with a novel real-time cross-linked peptide identification strategy", J Proteome Res, 12, pp.1569~1579 (2013)
21. Woodman CB, "The natural history of cervical HPV infection : unresolved issues", Nat Rev Cancer, 7, pp.11~22 (2007)
22. Barreto CL, "Detection of human papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis", Arch Gynecol Obstet, 288, pp.643~648 (2013)
23. Higgins GD, "Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA", Lancet, 338, pp.910~913 (1991)
24. Riou G, "Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA", Lancet, 335, pp.1171~1174 (1990)
25. Stolnicu S, "International Endocervical Adenocarcinoma Criteria and Classification(IECC) : a new pathogenetic classification for invasive adenocarcinomas of the endocervix", Am J Surg Pathol, 42, pp.214~226 (2018)
26. Petitjean A, "TP53 mutations in human cancers : functional selection and impact on cancer prognosis and outcomes", Oncogene, 26, pp.2157~2165 (2007)
27. Reed N, "British Gynaecological Cancer Society(BGCS)cervical cancer guidelines : recommendations for practice", Eur J Obstet Gynecol Reprod Biol, 256, pp.433~465 (2021)
28. Marth C, "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28, pp.iv72~iv83 (2017)
29. Yeung AR, "Improvement in patient-reported outcomes with intensity-modulated radiotherapy(RT)compared with standard RT : a report from the NRG Oncology RTOG 1203 Study", J Clin Oncol, 38, pp.1685~1692 (2020)
30. Yetkin-Arik B, "Angiogenesis in gynecological cancers and the options for antiangiogenesis therapy", Biochim Biophys Acta Rev Cancer, 1875, pp.188446~ (2021)
31. Barlesi F, "Maintenance bevacizumab-pemetrexed after first-line cisplatinpemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer : updated survival analysis of the AVAPERL(MO22089)randomized phase III trial", Ann Oncol, 25, pp.1044~1052 (2014)
32. Chung HC, "Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer : results from the phase II KEYNOTE-158study", J Clin Oncol, 37, pp.1470~1478 (2019)
33. Mezache L, "Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers", Mod Pathol, 28, pp.1594~1602 (2015)
34. Wendel Naumann R, "Advances in immunotherapy for cervical cancer", Curr Opin Oncol, 32, pp.481~487 (2020)
35. Colombo N, "Pembrolizumab for persistent, recurrent, or metastatic cervical cancer", N Engl J Med, 385, pp.1856~1867 (2021)
36. Da Silva DM, "Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation(GOG-9929)", Clin Cancer Res, 26, pp.5621~5630 (2020)
37. Bonaventura P, "Cold tumors : a therapeutic challenge for immunotherapy", Front Immunol, 10, pp.168~ (2019)
38. Shimada M, "Impact of histopathological risk factors on the treatment of stage IB-IIB uterine cervical cancer", Tohoku J Exp Med, 252, pp.339~351 (2020)
39. Arezzo F, "HPV-negative cervical cancer : a narrative review", Diagnostics(Basel), 11, pp.952~ (2021)
40. Meijer CJ, "Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older", Int J Cancer, 124, pp.516~520 (2009)
41. Poljak M, "Nucleic acid tests for the detection of alpha human papillomaviruses", Vaccine, 30(Suppl 5), pp.F100~F106 (2012)
42. Gheit T, "Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types", J Clin Microbiol, 44, pp.2025~2031 (2006)
43. Prigge ES, "Diagnostic accuracy of p16(INK4a)immunohistochemistry in oropharyngeal squamous cell carcinomas : a systematic review and meta-analysis", Int J Cancer, 140, pp.1186~1198 (2017)
44. Klaes R, "Overexpression of p16(INK4A)as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri", Int J Cancer, 92, pp.276~284 (2001)
45. Jedpiyawongse A, "Immunohistochemical overexpression of p16 protein associated with cervical cancer in Thailand", Asian Pac J Cancer Prev, 9, pp.625~630 (2008)
46. Alos L, "Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome", Cancer, 115, pp.2701~2709 (2009)
47. Larque AB, "High-risk human papillomavirus is transcriptionally active in a subset of sinonasal squamous cell carcinomas", Mod Pathol, 27, pp.343~351 (2014)
48. Pirog EC, "Diagnosis of HPV-negative, gastric-type adenocarcinoma of the endocervix", Methods Mol Biol, 1249, pp.213~219 (2015)
49. Sak K, "Characteristic features of cytotoxic activity of flavonoids on human cervical cancer cells", Asian Pac J Cancer Prev, 15, pp.8007~8019 (2014)
50. Lohmussaar K, "Humanderived model systems in gynecological cancer research", Trends Cancer, 6, pp.1031~1043 (2020)
51. Arbeit JM, "Mouse models of cervical cancer", Comp Med, 53, pp.256~258 (2003)
52. Sharma RK, "SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model", Vaccine, 28, pp.5794~5802 (2010)
53. Immel TA, "Synthesis and X-ray structure analysis of a heptacoordinate titanium(IV)-bis-chelate with enhanced in vivo antitumor efficacy", Chem Commun(Camb), 48, pp.5790~5792 (2012)
54. Zhao X, "An animal model of buccal mucosa cancer and cervical lymph node metastasis induced by U14 squamous cell carcinoma cells", Exp Ther Med, 5, pp.1083~1088 (2013)
55. Pappa KI, "High resolution proteomic analysis of the cervical cancer cell lines secretome documents deregulation of multiple proteases", Cancer Genomics Proteomics, 14, pp.507~521 (2017)
56. Chaudary N, "Establishment of orthotopic primary cervix cancer xenografts", Methods Mol Biol, 1249, pp.381~391 (2015)
57. Chen L, "Integrated analysis of HPV-mediated immune alterations in cervical cancer", Gynecol Oncol, 149, pp.248~255 (2018)
58. Roman M, "KRAS oncogene in non-small cell lung cancer : clinical perspectives on the treatment of an old target", Mol Cancer, 17, pp.33~ (2018)
59. Pirog EC, "Cervical adenocarcinoma : diagnosis of human papillomavirus-positive and human papillomavirusnegative tumors", Arch Pathol Lab Med, 141, pp.1653~1667 (2017)
60. Lin M, "Gastric-type endocervical adenocarcinoma : review of clinicopathologic characteristics and recent advances", J Gynecol Res Obstet, 6, pp.72~75 (2020)
61. Chumduri C, "Opposing Wnt signals regulate cervical squamocolumnar homeostasis and emergence of metaplasia", Nat Cell Biol, 23, pp.184~197 (2021)
62. Lohmussaar K, "Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer", Cell Stem Cell, 28, pp.1380~1396 (2021)
63. Maru Y, "Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma", Cancer Sci, 110, pp.2992~3005 (2019)
64. Li C, "The role of Exosomal miRNAs in cancer", J Transl Med, 20, pp.6~ (2022)
65. Bhat A, "Transcriptome analysis of cervical cancer exosomes and detection of HPVE6*I transcripts in exosomal RNA", BMC Cancer, 22, pp.164~ (2022)
66. Jimenez-Avalos JA, "Circulating exosomal MicroRNAs : New non-invasive biomarkers of non-communicable disease", Mol Biol Rep, 48, pp.961~967 (2021)
67. Bhat A, "Exosomes from cervical cancer cells facilitate pro-angiogenic endothelial reconditioning through transfer of Hedgehog-GLI signaling components", Cancer Cell Int, 21, pp.319~ (2021)
68. Zhang Y, "Exosomes : biogenesis, biologic function and clinical potential", Cell Biosci, 9, pp.19~ (2019)
69. Wu XG, "Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma", Angiogenesis, 22, pp.397~410 (2019)
70. Zhang J, "Exosomal long noncoding RNAs are differentially expressed in the cervicovaginal lavage samples of cervical cancer patients", J Clin Lab Anal, 30, pp.1116~1121 (2016)
71. Thery C, "Exosomes : composition, biogenesis and function", Nat Rev Immunol, 2, pp.569~579 (2002)

관련 논문AI추천